
Last updated: 17 November 2026 | Author: Prashant Tyagi (Stem Cell Biotechnology Specialist, 10+ years) and Dr. Pallavee Senior Consultant | Ophthalmologist & Eye Surgeon 22+ Years Experience
Choroideremia is a rare inherited eye disease that slowly damages the retina and the layer of blood vessels beneath it. It mainly affects males, often beginning with trouble seeing at night in the teens and slowly narrowing the field of vision over decades. It is easy to confuse with retinitis pigmentosa, which is why a correct diagnosis matters. This guide explains what choroideremia is, how it is diagnosed, what research is exploring and how to approach treatment claims.
Quick Navigation
Choroideremia is caused by changes in the CHM gene on the X chromosome. This gene makes a protein called REP1, which cells in the retina and nearby tissues need to function. Without it, the light-sensing cells, the retinal pigment epithelium and the choroid gradually degenerate, starting at the edges of the retina and moving inwards. Our partner site has a condition overview of choroideremia.
Because the CHM gene is on the X chromosome, males who inherit the changed gene usually have the disease. Females who carry one changed copy are usually carriers with mild or no symptoms, though some show patchy retinal changes and a few have noticeable vision problems. A carrier mother has a chance with each pregnancy of passing the change to a child. Genetic counselling explains the risks.
| Stage | What happens |
|---|---|
| Childhood to teens | Night blindness, often the first sign |
| Teens to twenties | Peripheral (side) vision starts to narrow while central vision is preserved |
| Middle age | Visual field narrows further; central vision may begin to decline |
| Later life | Significant vision loss is common, but the speed and timing vary between people |
Many people with choroideremia keep good central vision into their thirties or forties, which is why it can be a long journey with changing needs.
| Test | What it may show |
|---|---|
| Dilated eye examination | Patchy loss of the retina and choroid, often described as scalloped areas of atrophy at the edges |
| Fundus autofluorescence | Shows areas of surviving and lost tissue, helpful to track over time |
| OCT | Thinning of retinal and choroidal layers |
| Visual field test | Peripheral field loss with a central island |
| Electroretinogram (ERG) | Reduced rod and cone responses |
| Genetic testing (CHM gene) | Confirms the diagnosis; allows carrier testing and counselling |
| Feature | Choroideremia | Retinitis pigmentosa |
|---|---|---|
| Usual inheritance | X-linked, males mainly affected | Several patterns: dominant, recessive or X-linked |
| Early symptom | Night blindness | Night blindness |
| Retinal appearance | Patchy loss of retina and choroid | Bone-spicule pigment, thin vessels and a pale disc |
| Genetic cause | CHM gene | Many genes |
| Genetic testing role | Confirms diagnosis and carrier status | Identifies the gene among many |
Learn about the wider group of conditions on our retinitis pigmentosa and rod and cone dystrophy pages.
Because choroideremia comes from a single gene, it has been a leading target for gene therapy research. Early trials delivered a working copy of the CHM gene to the retina and showed encouraging safety results in small groups. A large later trial of one gene therapy did not meet its main goal, and research continues with other approaches. Other studies are looking at small molecules, antioxidant strategies and cell-based methods. None is yet an established standard treatment. Registered trials can be searched on international registries and on the Clinical Trials Registry – India.
Stem cell therapy is investigational for choroideremia. It cannot replace a missing gene in the retinal cells, and the evidence is limited and varies. Some patients are advised that stem cells may support remaining retinal tissue, but results differ and no provider can guarantee improvement. The retina is delicate, and there are documented cases of serious harm after unregulated injections in the eye. If you wish to discuss options, bring your genetic report, visual fields, OCT and ERG, and expect an honest assessment of whether any approach is reasonable. See our page on stem cell therapy in India.
Women are usually carriers with mild or no symptoms, but some have noticeable changes. Carrier testing and an eye examination can clarify.
Choroideremia progresses slowly, and many people keep useful central vision for decades. Outcomes vary.
No. Gene therapy research has been promising in parts, but no cure is established yet.
Yes, it confirms the diagnosis, separates it from retinitis pigmentosa and allows counselling.
Yes. Use our report upload page or the contact page.

